282 related articles for article (PubMed ID: 34520029)
21. Buprenorphine prescribing practice trends and attitudes among New York providers.
Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
[TBL] [Abstract][Full Text] [Related]
22. 2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services.
Zuckerman AD; Mourani J; Smith A; Ortega M; Donovan JL; Gazda NP; Tong K; Simonson D; Kelley T; DeClercq J; Choi L; Pierce G
Am J Health Syst Pharm; 2023 Jun; 80(13):827-841. PubMed ID: 36999452
[TBL] [Abstract][Full Text] [Related]
23. Utility of an integrated health system specialty pharmacy in provision of extended-release buprenorphine for patients with opioid use disorder.
Shah R; Hendrickson S; Fanucchi L; Lofwall M; Platt T; Rhudy C
Am J Health Syst Pharm; 2023 Jan; 80(1):e59-e66. PubMed ID: 36149825
[TBL] [Abstract][Full Text] [Related]
24. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
25. Opioid prescription underfilling among retail pharmacies.
Reisfield G; Paulian G; Merlo L; Bertholf R; Wilson G
Pain Med; 2010 Apr; 11(4):586-90. PubMed ID: 20113412
[TBL] [Abstract][Full Text] [Related]
26. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan.
Nau DP; Chi C; Mallya U; Kirking DM
J Manag Care Pharm; 2007 Mar; 13(2):135-41. PubMed ID: 17330974
[TBL] [Abstract][Full Text] [Related]
27. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
[TBL] [Abstract][Full Text] [Related]
28. Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.
Stein BD; Saloner B; Kerber R; Sorbero M; Gordon AJ
Ann Emerg Med; 2022 May; 79(5):441-450. PubMed ID: 35305851
[TBL] [Abstract][Full Text] [Related]
29. First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.
Uosukainen H; Bell JS; Laitinen K; Tacke U; Ilomäki J; Turunen JH
Int J Drug Policy; 2013 Sep; 24(5):492-7. PubMed ID: 23567099
[TBL] [Abstract][Full Text] [Related]
30. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic.
James JR; Marolf M; Klein JW; Blalock KL; Merrill JO; Tsui JI
Subst Use Misuse; 2021; 56(11):1569-1575. PubMed ID: 34282999
[TBL] [Abstract][Full Text] [Related]
31. Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US.
Weiner SG; Qato DM; Faust JS; Clear B
JAMA Netw Open; 2023 May; 6(5):e2316089. PubMed ID: 37234009
[TBL] [Abstract][Full Text] [Related]
32. Addressing the opioid crisis: An assessment of clinicians' training experience, practices, and attitudes within a large healthcare organization.
Kirane H; Drits E; Ahn S; Kapoor S; Morgenstern J; Conigliaro J; Enden J
J Opioid Manag; 2019; 15(3):193-204. PubMed ID: 31343721
[TBL] [Abstract][Full Text] [Related]
33. Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey.
Syros A; Rodriguez MG; Rennick AC; Dima GA; Gibstein AR; de la Parte L; Hermenau MG; Ciraldo KJ; Chueng TA; Tookes HE; Bartholomew TS; Serota DP
Addict Sci Clin Pract; 2022 Nov; 17(1):63. PubMed ID: 36401298
[TBL] [Abstract][Full Text] [Related]
34. Financial impact of patients enrolled in a medication adherence program at an independent community pharmacy.
Clifton CL; Branham AR; Hayes HH; Moose JS; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S109-S113. PubMed ID: 30006182
[TBL] [Abstract][Full Text] [Related]
35. Satisfaction with group-based appointments among patients with opioid use disorder in an urban buprenorphine clinic.
Akyar S; Nyaku A; Lao K; Ruthberg S; Zerbo EA
Subst Abus; 2022; 43(1):913-916. PubMed ID: 35226591
[No Abstract] [Full Text] [Related]
36. Patient satisfaction with pharmaceutical services at independent and chain pharmacies.
Briesacher B; Corey R
Am J Health Syst Pharm; 1997 Mar; 54(5):531-6. PubMed ID: 9066860
[TBL] [Abstract][Full Text] [Related]
37. Pharmacy-level barriers to implementing expedited partner therapy in Baltimore, Maryland.
Qin JZ; Diniz CP; Coleman JS
Am J Obstet Gynecol; 2018 May; 218(5):504.e1-504.e6. PubMed ID: 29410060
[TBL] [Abstract][Full Text] [Related]
38. Mapping Buprenorphine Access at Philadelphia Pharmacies.
Aronowitz SV; French R; Schachter A; Seeburger E; O'Donnell N; Perrone J; Lowenstein M
J Addict Med; 2024 May-Jun 01; 18(3):269-273. PubMed ID: 38345212
[TBL] [Abstract][Full Text] [Related]
39. An exploration of barriers, facilitators, and practical solutions for adopting medication synchronization into community pharmacies: A qualitative analysis.
Hughes TD; Cutrell S; Minshew LM; Brown P; Ferreri SP
Explor Res Clin Soc Pharm; 2022 Mar; 5():100111. PubMed ID: 35478527
[TBL] [Abstract][Full Text] [Related]
40. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
Currie JM; Schnell MK; Schwandt H; Zhang J
JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
